Please choose your delivery country and your customer group
Penetrating wounds are the most common injury incurred in military combat, resulting from both gunshot and shell fragmentation, and these wounds often result in mortality. However, in the future such fatal wounds might be treatable using advanced biotechnologies to control haemorrhaging and reduce blood-loss until medical evacuation can be completed. This study evaluates the operational implications of a new kind of intravenous coagulating agent. The efficacy of the drug is benchmarked against casualty data from the Vietnam War and assessed through a process of simulation in an agent-based combat environment. Finally, we conclude that the drug reduces mortality by 7%, within those casualties which are responsive to treatment.